Profile data is unavailable for this security.
About the company
Shanghai Allist Pharmaceuticals Co Ltd is a China-based company principally engaged in oncology treatment. The Company has developed a pipeline of small molecule targeted drugs for non-small cell lung cancer. The main products include Furmonertinib Mesilate tablets, golecilex and pratinib capsules. The primary business includes sales of anti-cancer products, as well as technology licensing and services. The Company mainly operates in the domestic market.
- Revenue in CNY (TTM)4.76bn
- Net income in CNY1.98bn
- Incorporated2004
- Employees1.42k
- LocationShanghai Allist Pharmaceuticals Co LtdNo. 268 Lingxiaohua RoadZhoupu Town, Pudong New AreaSHANGHAI 201318ChinaCHN
- Phone+86 2 180423292
- Fax+86 2 180423291
- Websitehttps://www.allist.com.cn/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dizal Pharmaceutical Co Ltd | 607.75m | -867.44m | 25.01bn | 852.00 | -- | 17.17 | -- | 41.15 | -2.01 | -2.01 | 1.40 | 3.14 | 0.2644 | 0.8102 | 5.84 | 713,322.50 | -37.97 | -46.55 | -55.30 | -56.24 | 95.12 | 90.63 | -143.64 | -825.75 | 2.42 | -111.09 | 0.4239 | -- | 294.24 | 54.40 | 23.63 | -- | 58.33 | -- |
| Joinn Laboratories China Co Ltd | 1.67bn | 225.09m | 25.96bn | 2.65k | 110.01 | 3.46 | -- | 15.56 | 0.3405 | 0.3405 | 2.37 | 10.84 | 0.175 | 0.7843 | 6.03 | 629,011.80 | 2.36 | 6.60 | 2.72 | 7.92 | 24.63 | 41.87 | 13.47 | 25.98 | 3.06 | -- | 0.0039 | 23.59 | -15.07 | 25.85 | -81.34 | -16.89 | 16.27 | -19.46 |
| Wuhan Healthgen Biotechnology Corp | 23.39m | -160.81m | 26.03bn | 215.00 | -- | 52.38 | -- | 1,113.00 | -0.4498 | -0.4498 | 0.0654 | 1.39 | -- | -- | -- | 131,386.80 | -- | -- | -- | -- | 41.12 | -- | -687.60 | -- | 0.359 | -30.87 | 0.5497 | -- | 3.92 | -- | 19.04 | -- | -- | -- |
| Biocytogen Phrmutcls (Beijing) Co Ltd | 1.33bn | 249.94m | 29.11bn | 1.28k | 130.22 | 33.36 | 74.95 | 21.86 | 0.5593 | 0.5593 | 2.98 | 2.18 | -- | -- | -- | 1,215,939.00 | -- | -- | -- | -- | 76.56 | -- | 18.77 | -- | 1.11 | 14.77 | 0.5281 | -- | 36.76 | -- | 108.76 | -- | -- | -- |
| Shanghai Allist Pharmaceuticals Co Ltd | 4.76bn | 1.98bn | 44.13bn | 1.42k | 22.26 | 6.79 | -- | 9.28 | 4.41 | 4.41 | 10.57 | 14.44 | 0.7497 | 5.75 | 13.98 | 3,357,423.00 | 31.24 | 10.89 | 34.76 | 11.75 | 95.37 | 96.19 | 41.68 | 27.72 | 5.34 | -- | 0.0006 | 24.71 | 76.29 | 462.87 | 121.97 | -- | 24.77 | -- |
| RemeGen Co Ltd | 2.23bn | -947.63m | 50.66bn | 3.00k | -- | 24.34 | -- | 22.74 | -1.75 | -1.75 | 4.10 | 4.12 | 0.3812 | 0.541 | 6.40 | 742,854.40 | -16.21 | -19.20 | -27.09 | -23.96 | 82.97 | 81.06 | -42.54 | -87.98 | 0.7278 | -9.93 | 0.4848 | -- | 58.54 | 223.78 | 2.84 | -- | 32.40 | -- |
Data as of Feb 06 2026. Currency figures normalised to Shanghai Allist Pharmaceuticals Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
13.60%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| China Asset Management Co., Ltd.as of 30 Jun 2025 | 14.17m | 3.15% |
| E Fund Management Co., Ltd.as of 30 Jun 2025 | 11.92m | 2.65% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2025 | 10.81m | 2.40% |
| JPMorgan Asset Management (China) Co Ltd.as of 30 Jun 2025 | 7.51m | 1.67% |
| ICBC UBS Asset Management Co. Ltd.as of 30 Jun 2025 | 4.21m | 0.94% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2025 | 3.86m | 0.86% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 2.70m | 0.60% |
| Yinhua Fund Management Co., Ltd.as of 30 Jun 2025 | 2.24m | 0.50% |
| Ping An Fund Management Co., Ltd.as of 30 Jun 2025 | 2.12m | 0.47% |
| Huatai-PineBridge Fund Management Co., Ltd.as of 30 Jun 2025 | 1.66m | 0.37% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
